MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Even if it's not a huge purchase, we think it was good to see that Sangeetha Sundaramoorthy, the MD & Whole Time Director of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) recently shelled out ₹240k to buy stock, at ₹37.08 per share. Although the purchase is not a big one, increasing their shareholding by only 2.8%, it can be interpreted as a good sign.

Check out our latest analysis for Lotus Eye Hospital and Institute

Lotus Eye Hospital and Institute Insider Transactions Over The Last Year

While no particular insider transaction stood out, we can still look at the overall trading.

In the last twelve months Lotus Eye Hospital and Institute insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

Lotus Eye Hospital and Institute is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Does Lotus Eye Hospital and Institute Boast High Insider Ownership?

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Lotus Eye Hospital and Institute insiders own 70% of the company, currently worth about ₹573m based on the recent share price. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

What Might The Insider Transactions At Lotus Eye Hospital and Institute Tell Us?

It's certainly positive to see the recent insider purchases. We also take confidence from the longer term picture of insider transactions. But we don't feel the same about the fact the company is making losses. Once you factor in the high insider ownership, it certainly seems like insiders are positive about Lotus Eye Hospital and Institute. One for the watchlist, at least! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Lotus Eye Hospital and Institute. To assist with this, we've discovered 2 warning signs that you should run your eye over to get a better picture of Lotus Eye Hospital and Institute.

Of course Lotus Eye Hospital and Institute may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

If you decide to trade Lotus Eye Hospital and Institute, use the lowest-cost* platform that is rated #1 Overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account. Promoted

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
^*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.